Cell culture methods and compositions for antibody production
WO2020252072A1
Antibody purification methods and compositions thereof
WO2020252069A1
METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY
WO2020215019A1
Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2020176772A1
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
WO2020176643A1
Compounds useful as adjuvants
JP2020079299A
Proteasome inhibitor
WO2020154540A1
Anti-cd38 antibodies
US2020231650A1
Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
WO2020014139A1
Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies
EP3803296A1
Systems and methods for automated tracking and optimization of global manufacturing and supply based on impacts of post-approval changes
SG11202009785YA
Systems and methods for filling containers
WO2019109016A1
Biomarkers and methods for treatment with nae inhibitors
WO2019060536A1
Cocrystal forms of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
BR112019025355A2
METHOD FOR THE PRODUCTION OF OTICALLY ACTIVE COMPOUND
BR112019024875A2
METHODS FOR THE TREATMENT OF CHRONIC RESERVOIR ILEIT
WO2018213258A1
Treatment of merlin-deficient tumors using nae inhibitors
CN110785169A
Treatment of gastroparesis with triazaspiro [4.5] decanones
KR20190141148A
How to treat pediatric disorders
WO2018144791A1
Combination of vps34 inhibitors and mtor inhibitors
